Metabolic Impacts of Oral Contraceptives A Comprehensive Review of Current Evidence
DOI:
https://doi.org/10.12775/QS.2024.34.55987Keywords
carbohydrate metabolism, lipoproteins, lipids, Oral contraceptiveAbstract
Introduction and objective: Oral hormonal contraception (COC) is a highly popular, as well as extensive group of medications. A significant impact of chronic COC therapy on parameters of lipid metabolism, carbohydrates, binding globulins, coagulation system and body weight of patients has been proven. Given the continuously increasing number of women using COC, initiating therapy at progressively younger ages it is reasonable to investigate the impact of individual medications on patients’ organisms completing knowledge with conclusions from newly conducted research, as well as the influence of new types of drugs on the studied indicators.
Material and method: The literature was reviewed in the Pubmed database, GoogleScholar, the positions of the Polish gynecological society with the use of keywords.
State of knowledge: The use of COC is widespread among women. According to the citied studies, over 80% of premenopausal women have declared using oral contraceptives. Typically, COCs consist of a combination of estrogen and progestin components, offering various possible combinations and dosing regimens. Despite their high efficacy in preventing pregnancy, their impact on lipid and carbohydrate metabolism, as well as consequences remains incompletely understood. Older generations of progestins, due to their similarity to testosterone, can cause negative androgenic effects, while more recent progestins are expected to be neutral.
Summary: Each type of therapy is characterized by individual impact on the patients’ organism, however, the majority of progestins affect the increase of triglycerides, HDL and have ambiguous effect on LDL. COC has a limited influence on BMI, carbohydrate metabolism, coagulation system and glycemia.
References
Silva-Bermudez LS, Toloza FJK, Perez-Matos MC, de Souza RJ, Banfield L, Vargas-Villanueva A, Mendivil CO. Effects of oral contraceptives on metabolic parameters in adult premenopausal women: a meta-analysis. Endocr Connect. 2020 Oct;9(10):978-998. doi: 10.1530/EC-20-0423. PMID: 33048062; PMCID: PMC7576645.
Campesi I, Montella A, Sotgiu G, Saderi L, Tonolo G, Seghieri G, Franconi F. Smoking and combined oral contraceptives should be considered as an independent variable in sex and gender-oriented studies. Toxicol Appl Pharmacol. 2022 Dec 15;457:116321. doi: 10.1016/j.taap.2022.116321. Epub 2022 Nov 22. PMID: 36423693.
Janaud A, Rouffy J, Upmalis D, Dain MP. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel. Acta Obstet Gynecol Scand Suppl. 1992;156:33-8. doi: 10.3109/00016349209156513. PMID: 1324555.
Steinmetz A, Bauer K, Jürgensen R, Kaffarnik H. Low-dose oral contraceptives lower plasma levels of apolipoprotein E. Eur J Obstet Gynecol Reprod Biol. 1990 Nov;37(2):155-62. doi: 10.1016/0028-2243(90)90108-d. PMID: 2147014.
Junge W, Mellinger U, Parke S, Serrani M. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study. Clin Drug Investig. 2011;31(8):573-584. doi: 10.2165/11590220-000000000-00000. PMID: 21721593.
Wiegratz I, Lee JH, Kutschera E, Bauer HH, von Hayn C, Moore C, Mellinger U, Winkler UH, Gross W, Kuhl H. Effect of dienogest-containing oral contraceptives on lipid metabolism. Contraception. 2002 Mar;65(3):223-9. doi: 10.1016/s0010-7824(01)00310-9. PMID: 11929644.
Shahnazi M, Farshbaf-Khalili A, Pourzeinali-Beilankouh S, Sadrimehr F. Effects of Second and Third Generation Oral Contraceptives on Lipid and Carbohydrate Metabolism in Overweight and Obese Women: A Randomized Triple-Blind Controlled Trial. Iran Red Crescent Med J. 2016 Jun 19;18(9):e36982. doi: 10.5812/ircmj.36982. PMID: 28144464; PMCID: PMC5253509.
Song S, Chen JK, Yang PJ, He ML, Li LM, Fan BC, Rekers H, Fotherby K. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel. Contraception. 1992 Jun;45(6):523-32. doi: 10.1016/0010-7824(92)90103-z. PMID: 1535580.
Skouby SO, Endrikat J, Düsterberg B, Schmidt W, Gerlinger C, Wessel J, Goldstein H, Jespersen J. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel. Contraception. 2005 Feb;71(2):111-7. doi: 10.1016/j.contraception.2004.08.017. PMID: 15707560.
Scharnagl H, Petersen G, Nauck M, Teichmann AT, Wieland H, März W. Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 microg or 30 microg) and levonorgestrel (100 microg or 150 microg) on lipoprotein metabolism. Contraception. 2004 Feb;69(2):105-13. doi: 10.1016/j.contraception.2003.10.004. PMID: 14759614.
Endrikat J, Klipping C, Cronin M, Gerlinger C, Ruebig A, Schmidt W, Düsterberg B. An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. Contraception. 2002 Mar;65(3):215-21. doi: 10.1016/s0010-7824(01)00316-x. PMID: 11929643.
Loke DF, Ng CS, Samsioe G, Holck S, Ratnam SS. A comparative study of the effects of a monophasic and a triphasic oral contraceptive containing ethinyl estradiol and levonorgestrel on lipid and lipoprotein metabolism. Contraception. 1990 Nov;42(5):535-54. doi: 10.1016/0010-7824(90)90081-6. PMID: 2125546.
Notelovitz M, Feldman EB, Gillespy M, Gudat J. Lipid and lipoprotein changes in women taking low-dose, triphasic oral contraceptives: a controlled, comparative, 12-month clinical trial. Am J Obstet Gynecol. 1989 May;160(5 Pt 2):1269-80. doi: 10.1016/s0002-9378(89)80012-2. PMID: 2655452.
Larsson-Cohn U, Wallentin L, Zador G. Plasma lipids and high density lipoproteins during oral contraception with different combinations of ethinyl estradiol and levonorgestrel. Horm Metab Res. 1979 Jul;11(7):437-40. doi: 10.1055/s-0028-1092755. PMID: 225252.
Kjaer A, Lebech AM, Borggaard B, Refn H, Pedersen LR, Schierup L, Bremmelgaard A. Lipid metabolism and coagulation of two contraceptives: correlation to serum concentrations of levonorgestrel and gestodene. Contraception. 1989 Dec;40(6):665-73. doi: 10.1016/0010-7824(89)90070-x. PMID: 2515940.
Flores-Rodriguez A, Diaz Gonzalez-Colmenero F, Garcia-Leal M, Saenz-Flores M, Burciaga-Jimenez E, Zuñiga-Hernandez JA, Alvarez-Villalobos NA, Rodríguez-Guajardo R, Morales-Martinez FA, Sordia-Hernandez LH, Rodriguez-Gutierrez R. Harms of third- and fourth-generation combined oral contraceptives in premenopausal women: A systematic review and meta-analysis. J Investig Med. 2023 Dec;71(8):871-888. doi: 10.1177/10815589231184227. Epub 2023 Jul 6. PMID: 37415461.
Kakis G, Powell M, Marshall A, Woutersz TB, Steiner G. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids. Int J Fertil Menopausal Stud. 1994 Sep-Oct;39(5):283-91. PMID: 7820162.
Amiri M, Nahidi F, Bidhendi-Yarandi R, Khalili D, Tohidi M, Ramezani Tehrani F. A comparison of the effects of oral contraceptives on the clinical and biochemical manifestations of polycystic ovary syndrome: a crossover randomized controlled trial. Hum Reprod. 2020 Jan 1;35(1):175-186. doi: 10.1093/humrep/dez255. PMID: 31916574
Amiri M, Ramezani Tehrani F, Nahidi F, Kabir A, Azizi F, Carmina E. Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: A meta-analysis comparing products containing cyproterone acetate with third generation progestins. Metabolism. 2017 Aug;73:22-35. doi: 10.1016/j.metabol.2017.05.001. Epub 2017 May 10. PMID: 28732568
Romualdi D, De Cicco S, Busacca M, Gagliano D, Lanzone A, Guido M. Clinical efficacy and metabolic impact of two different dosages of ethinyl-estradiol in association with drospirenone in normal-weight women with polycystic ovary syndrome: a randomized study. J Endocrinol Invest. 2013 Sep;36(8):636-41. doi: 10.1007/BF03346756. PMID: 24105072.
Regidor PA, Mueller A, Mayr M. Pharmacological and metabolic effects of drospirenone as a progestin-only pill compared to combined formulations with estrogen. Womens Health (Lond). 2023 Jan-Dec;19:17455057221147388. doi: 10.1177/17455057221147388. PMID: 36744531; PMCID: PMC9905034.
Palacios S, Colli E, Regidor PA. Metabolic and laboratory effects of a progestin-only pill containing drospirenone 4 mg in comparison to desogestrel 75 µg: a double-blind, double-dummy, prospective, randomised study. Eur J Contracept Reprod Health Care. 2021 Dec;26(6):454-461. doi: 10.1080/13625187.2021.1957094. Epub 2021 Aug 4. PMID: 34348526.
Kriplani A, Periyasamy AJ, Agarwal N, Kulshrestha V, Kumar A, Ammini AC. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. Contraception. 2010 Aug;82(2):139-46. doi: 10.1016/j.contraception.2010.02.009. Epub 2010 May 23. PMID: 20654754.
Klipping C, Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception. 2005 Jun;71(6):409-16. doi: 10.1016/j.contraception.2004.12.005. PMID: 15914128.
Gaspard U, Endrikat J, Desager JP, Buicu C, Gerlinger C, Heithecker R. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception. 2004 Apr;69(4):271-8. doi: 10.1016/j.contraception.2003.11.003. PMID: 15033400.
Yildizhan R, Yildizhan B, Adali E, Yoruk P, Birol F, Suer N. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure. Arch Gynecol Obstet. 2009 Aug;280(2):255-61. doi: 10.1007/s00404-008-0907-x. Epub 2009 Jan 6. PMID: 19125264.
Fruzzetti F, Perini D, Lazzarini V, Parrini D, Gambacciani M, Genazzani AR. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Fertil Steril. 2010 Oct;94(5):1793-8. doi: 10.1016/j.fertnstert.2009.10.016. PMID: 19931080.
Gemzell-Danielsson K, Cagnacci A, Chabbert-Buffet N, Douxfils J, Foidart JM, Kubba A, Lete Lasa LI, Mansour D, Neulen J, Neves J, Palma F, Römer T, Spaczyński R, Tóth V. A novel estetrol-containing combined oral contraceptive: European expert panel review. Eur J Contracept Reprod Health Care. 2022 Oct;27(5):373-383. doi: 10.1080/13625187.2022.2093850. Epub 2022 Jul 21. PMID: 35862627.
Köhler G, Göretzlehner G, Brachmann K. Lipid metabolism during treatment of endometriosis with the progestin dienogest. Acta Obstet Gynecol Scand. 1989;68(7):633-5. doi: 10.3109/00016348909013283. PMID: 2631529.
Cagnacci A, Ferrari S, Tirelli A, Zanin R, Volpe A. Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial. Contraception. 2009 Feb;79(2):111-6. doi: 10.1016/j.contraception.2008.09.002. Epub 2008 Oct 16. PMID: 19135567.
van den Ende A, Geurts TB, Kloosterboer HJ. A randomized cross-over study comparing pharmacodynamic and metabolic variables of a new combiphasic and a well-established triphasic oral contraceptive. Eur J Contracept Reprod Health Care. 1997 Sep;2(3):173-80. doi: 10.3109/13625189709167473. PMID: 9678089.
Petersen KR, Skouby SO, Pedersen RG. Desogestrel and gestodene in oral contraceptives: 12 months' assessment of carbohydrate and lipoprotein metabolism. Obstet Gynecol. 1991 Oct;78(4):666-72. PMID: 1833682.
Gevers Leuven JA, Dersjant-Roorda MC, Helmerhorst FM, de Boer R, Neymeyer-Leloux A, Havekes L. Estrogenic effect of gestodene- or desogestrel-containing oral contraceptives on lipoprotein metabolism. Am J Obstet Gynecol. 1990 Jul;163(1 Pt 2):358-62. doi: 10.1016/0002-9378(90)90582-r. PMID: 2142575.
Bertolini S, Elicio N, Cordera R, Gapitanio GL, Montagna G, Croce S, Saturnino M, Balestreri R, De Cecco L. Effects of three low-dose oral contraceptive formulations on lipid metabolism. Acta Obstet Gynecol Scand. 1987;66(4):327-32. doi: 10.3109/00016348709103647. PMID: 2962417.
Miccoli R, Orlandi MC, Fruzzetti F, Giampietro O, Melis G, Ricci C, Bertolotto A, Fioretti P, Navalesi R. Metabolic effects of three new low-dose pills: a six-month experience. Contraception. 1989 Jun;39(6):643-52. doi: 10.1016/0010-7824(89)90039-5. PMID: 2526717.
Cagnacci A, Ferrari S, Tirelli A, Zanin R, Volpe A. Route of administration of contraceptives containing desogestrel/etonorgestrel and insulin sensitivity: a prospective randomized study. Contraception. 2009 Jul;80(1):34-9. doi: 10.1016/j.contraception.2009.01.012. Epub 2009 Mar 17. PMID: 19501213.
van der Mooren MJ, Klipping C, van Aken B, Helmerhorst E, Spielmann D, Kluft C. A comparative study of the effects of gestodene 60 microg/ethinylestradiol 15 microg and desogestrel 150 microg/ethinylestradiol 20 microg on hemostatic balance, blood lipid levels and carbohydrate metabolism. Eur J Contracept Reprod Health Care. 1999 Nov;4 Suppl 2:27-35. doi: 10.3109/13625189909085267. PMID: 14677622.
März W, Jung-Hoffmann C, Heidt F, Gross W, Kuhl H. Changes in lipid metabolism during 12 months of treatment with two oral contraceptives containing 30 micrograms ethinylestradiol and 75 micrograms gestodene or 150 micrograms desogestrel. Contraception. 1990 Mar;41(3):245-58. doi: 10.1016/0010-7824(90)90066-5. PMID: 2138973.
Vexiau P, Vexiau-Robert D, Martineau I, Hardy N, Villette JM, Fiet J, Cathelineau G. Metabolic effect at six and twelve months of cyproterone acetate (2 mg) combined with ethinyl estradiol (35 micrograms) in 31 patients. Horm Metab Res. 1990 Apr;22(4):241-5. doi: 10.1055/s-2007-1004893. PMID: 2141001.
Patsch W, Brown SA, Gotto AM Jr, Young RL. The effect of triphasic oral contraceptives on plasma lipids and lipoproteins. Am J Obstet Gynecol. 1989 Nov;161(5):1396-401. doi: 10.1016/0002-9378(89)90703-5. PMID: 2686455.
Ozdemir S, Görkemli H, Gezginç K, Ozdemir M, Kiyici A. Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome. Int J Gynaecol Obstet. 2008 Oct;103(1):44-9. doi: 10.1016/j.ijgo.2008.05.017. Epub 2008 Jul 16. PMID: 18635183.
Giraudo F, Salinas A, Merino PM, Iñiguez G, López P, Castro A, Lardone MC, Cavada G, Cassorla F, Codner E. Subdermal Progestin Implant and an Oral Combined Hormonal Contraceptive in Youth with Type 1 Diabetes. J Pediatr Adolesc Gynecol. 2023 Nov 25:S1083-3188(23)00449-7. doi: 10.1016/j.jpag.2023.11.009. Epub ahead of print. PMID: 38012981
Wu L, Liu Y, Huang X, Lin K, Liu Y, Li Z, Wei T, Song L, Hua Y, Wang X. Oral contraceptives (OCs) in combination with metformin versus OCs alone on metabolism in nonobese polycystic ovary syndrome: A meta-analysis and systematic review of randomized controlled trials. Clin Endocrinol (Oxf). 2023 Jul;99(1):3-16. doi: 10.1111/cen.14895. Epub 2023 Apr 7. PMID: 36799083.
Maeda E, Koshiba A, Mori T, Ito F, Kataoka H, Okimura H, Sugahara T, Tarumi Y, Kusuki I, Khan KN, Kitawaki J. Atherosclerosis-related biomarkers in women with endometriosis: The effects of dienogest and oral contraceptive therapy. Eur J Obstet Gynecol Reprod Biol X. 2020 Apr 23;7:100108. doi: 10.1016/j.eurox.2020.100108. PMID: 32715291; PMCID: PMC7379146.
Larsson-Cohn U, Fåhraeus L, Wallentin L, Zador G. Effects of the estrogenicity of levonorgestrel/ethinylestradiol combinations of the lipoprotein status. Acta Obstet Gynecol Scand Suppl. 1982;105:37-40. doi: 10.3109/00016348209155316. PMID: 6805243.
März W, Gross W, Gahn G, Romberg G, Taubert HD, Kuhl H. A randomized crossover comparison of two low-dose contraceptives: effects on serum lipids and lipoproteins. Am J Obstet Gynecol. 1985 Oct 1;153(3):287-93. doi: 10.1016/s0002-9378(85)80114-9. PMID: 2931988.
Kauppinen-Mäkelin R, Kuusi T, Ylikorkala O, Tikkanen MJ. Contraceptives containing desogestrel or levonorgestrel have different effects on serum lipoproteins and post-heparin plasma lipase activities. Clin Endocrinol (Oxf). 1992 Feb;36(2):203-9. doi: 10.1111/j.1365-2265.1992.tb00959.x. PMID: 1533186.
Mhao NS, Al-Hilli AS, Hadi NR, Jamil DA, Al-Aubaidy HA. A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome. Diabetes Metab Syndr. 2016 Jan-Mar;10(1 Suppl 1):S95-8. doi: 10.1016/j.dsx.2015.10.001. Epub 2015 Nov 12. PMID: 26703220.
Teede HJ, Meyer C, Hutchison SK, Zoungas S, McGrath BP, Moran LJ. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy. Fertil Steril. 2010 Jan;93(1):184-91. doi: 10.1016/j.fertnstert.2008.09.034. Epub 2008 Nov 18. PMID: 19019358.
Klipping C, Duijkers I, Mawet M, Maillard C, Bastidas A, Jost M, Foidart JM. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. Contraception. 2021 Apr;103(4):213-221. doi: 10.1016/j.contraception.2021.01.001. Epub 2021 Jan 9. PMID: 33428907.
Vermeulen A, Rubens R. Effects of cyproterone acetate plus ethinylestradiol low dose on plasma androgens and lipids in mildly hirsute or acneic young women. Contraception. 1988 Oct;38(4):419-28. doi: 10.1016/0010-7824(88)90083-2. PMID: 2974791
Cachrimanidou AC, Hellberg D, Nilsson S, von Schoulz B, Crona N, Siegbahn A. Hemostasis profile and lipid metabolism with long-interval use of a desogestrel-containing oral contraceptive. Contraception. 1994 Aug;50(2):153-65. doi: 10.1016/0010-7824(94)90051-5. PMID: 7956214.
Kangasniemi MH, Arffman RK, Haverinen A, Luiro K, Hustad S, Heikinheimo O, Tapanainen JS, Piltonen TT. Effects of estradiol- and ethinylestradiol-based contraceptives on adrenal steroids: A randomized trial. Contraception. 2022 Dec;116:59-65. doi: 10.1016/j.contraception.2022.08.009. Epub 2022 Sep 7. PMID: 36084710.
Ågren UM, Anttila M, Mäenpää-Liukko K, Rantala ML, Rautiainen H, Sommer WF, Mommers E. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in comparison to one containing levonorgestrel and ethinylestradiol on markers of endocrine function. Eur J Contracept Reprod Health Care. 2011 Dec;16(6):458-67. doi: 10.3109/13625187.2011.614363. Epub 2011 Sep 26. PMID: 21942708; PMCID: PMC3233273.
Battaglia C, Mancini F, Fabbri R, Persico N, Busacchi P, Facchinetti F, Venturoli S. Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenone-ethinylestradiol or contraceptive vaginal ring. A prospective, randomized, pilot study. Fertil Steril. 2010 Sep;94(4):1417-1425. doi: 10.1016/j.fertnstert.2009.05.044. Epub 2009 Jul 9. PMID: 19591981.
Petersen KR, Christiansen E, Madsbad S, Skouby SO, Andersen LF, Jespersen J. Metabolic and fibrinolytic response to changed insulin sensitivity in users of oral contraceptives. Contraception. 1999 Dec;60(6):337-44. doi: 10.1016/s0010-7824(99)00107-9. PMID: 10715368.
Aydin K, Cinar N, Aksoy DY, Bozdag G, Yildiz BO. Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination. Contraception. 2013 Mar;87(3):358-62. doi: 10.1016/j.contraception.2012.07.005. Epub 2012 Aug 13. PMID: 22898361.
Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod. 2002 Jul;17(7):1729-37. doi: 10.1093/humrep/17.7.1729. PMID: 12093831.
Feng W, Jia YY, Zhang DY, Shi HR. Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. Gynecol Endocrinol. 2016;32(2):147-50. doi: 10.3109/09513590.2015.1101441. Epub 2015 Oct 28. PMID: 26507097
Song J, Ruan X, Gu M, Wang L, Wang H, Mueck AO. Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecol Endocrinol. 2018 May;34(5):413-417. doi: 10.1080/09513590.2017.1407752. Epub 2017 Nov 24. PMID: 29172796.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Karol Zagórski, Nina Skalska-Dziobek, Mateusz Kozik, Weronika Małagocka, Karolina Chybowska, Mateusz Orłowski , Maria Naruszewicz, Aleksandra Midro, Przemysław Cetnarowski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 53
Number of citations: 0
